☆ 4.5 Article

Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

In vitro and in vivo comparison of eravacycline- and tigecycline-based combination therapies for tigecycline-resistant Acinetobacter baumannii

Ti Yin et al.

Summary: Combination therapies of eravacycline and tigecycline have shown effectiveness against XDR Acinetobacter baumannii infections, but no additional benefits compared to monotherapy were observed in a mouse model. Colistin remains the last resort for XDR-A treatment, but novel antibiotics are urgently needed due to the rapid development of resistance in A. baumannii.

JOURNAL OF CHEMOTHERAPY (2022)

添加到收藏夹

Article Immunology

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece

Dimitra Petropoulou et al.

Summary: This study evaluated the in vitro activity of the sulbactam-durlobactam (SD) combination against carbapenem-resistant A. baumannii isolates. SD demonstrated the lowest minimum inhibitory concentration (MIC90) and showed potential utility for the treatment of infections caused by A. baumannii. The addition of imipenem further enhanced the activity of SD.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)

添加到收藏夹

Article Microbiology

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Marco Falcone et al.

Summary: Cefiderocol appears to be a promising therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, with a potential protective effect on 30-day mortality. However, further studies are needed to address the issue of microbiological failure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Immunology

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Pranita D. Tamma et al.

Summary: This article provides updated guidance on the treatment of infections caused by ESBL-E, CRE, and DTR-P. aeruginosa. The guidance was developed by a panel of infectious diseases specialists and includes preferred and alternative treatment recommendations. The document emphasizes the importance of consulting with an infectious diseases specialist for the treatment of antimicrobial-resistant infections.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Microbiology

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021

James A. Karlowsky et al.

Summary: Sulbactam-durlobactam demonstrated potent antibacterial activity against geographically diverse clinical isolates of Acinetobacter baumannii-calcoaceticus complex (ABC), including carbapenem-non-susceptible and multidrug-resistant (MDR) isolates.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia

Yanling Deng et al.

Summary: This study found that patients aged over 75, those undergoing invasive catheter placement and mechanical ventilation had higher mortality rates. Combination therapy with tigecycline can lower the mortality rate for patients with CRAB, while combination therapy with sulbactam can reduce mortality, especially with high doses.

BMC INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Infectious Diseases

Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis

Jiating Liu et al.

Summary: The study showed that combination therapy with high-dose sulbactam and additional antibacterial agents had promising efficacy in treating MDR-AB or XDR-AB infections, while colistin-based combinations remained the mainstay in most studies. However, colistin combined with other antibacterial agents was associated with a higher risk of nephrotoxicity.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Microbiology

Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model

Maya Beganovic et al.

Summary: Triple therapy with high-dose minocycline, continuous-infusion sulbactam, and polymyxin B demonstrated the most significant kill against carbapenem-resistant Acinetobacter baumannii, with no regrowth and minimal resistance development in an in vitro pharmacodynamic model.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Review Infectious Diseases

Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists

Jacinda C. Abdul-Mutakabbir et al.

Summary: This review highlights the lack of defined preferred treatment for CRAB infections and advocates for combination therapy to address resistance issues. It also emphasizes the importance of considering various factors such as infection site, severity of illness, and local epidemiology in selecting treatment regimens. Emerging therapies such as durlobactam-sulbactam, cefiderocol combination regimens, and bacteriophage therapy show promising potential in managing CRAB infections and reducing reliance on polymyxins in the future.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Article Infectious Diseases

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates

Fernando Pasteran et al.

Summary: The study focuses on testing different combinations of sulbactam with beta-lactamase inhibitors to treat multi-drug resistant Acinetobacter clinical isolates. Results show that sulbactam combined with avibactam or relebactam can restore sulbactam activity against the isolates, offering new options for treating infections caused by widespread oxacillinases and metallo-beta-lactamases producers.

ANTIBIOTICS-BASEL (2021)

添加到收藏夹

Review Microbiology

The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of Clinical Evidence

Paraskevi C. Fragkou et al.

MICROORGANISMS (2019)

添加到收藏夹

Review Medicine, General & Internal

Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases A meta-analysis

Jinhong Gong et al.

MEDICINE (2019)

添加到收藏夹

Article Infectious Diseases

In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii

Harald Seifert et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)

添加到收藏夹

Review Infectious Diseases

Interplay between Colistin Resistance, Virulence and Fitness in Acinetobacter baumannii

Gabriela Jorge Da Silva et al.

ANTIBIOTICS-BASEL (2017)

添加到收藏夹

Article Microbiology

High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model

Justin R. Lenhard et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent

George G. Zhanel et al.

DRUGS (2016)

添加到收藏夹

Review Infectious Diseases

Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis

Wentao Ni et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)

添加到收藏夹

Article Infectious Diseases

Molecular Characterization of Invasive Carbapenem-Resistant Acinetobacter baumannii from a Tertiary Care Hospital in South India

Saranya Vijayakumar et al.

INFECTIOUS DISEASES AND THERAPY (2016)

添加到收藏夹

Article Microbiology

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

William F. Penwell et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

添加到收藏夹

Review Infectious Diseases

Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis

Haiqing Chu et al.

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2013)

添加到收藏夹

Article Microbiology

Synergy Testing by Etest, Microdilution Checkerboard, and Time-Kill Methods for Pan-Drug-Resistant Acinetobacter baumannii

Madhuri M. Sopirala et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)

添加到收藏夹

Article Microbiology

Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline

AC Fluit et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.